74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Moderna Inc
Closed
SectorHealthcare
27.34 3.09
Overview
Share price change
24h
Min
26.33
Max
27.36
Income | -1.1B -1.1B |
|---|---|
Sales | -894M 966M |
P/E Sector Avg | 35.86 57.333 |
EPS | -2.91 |
Profit margin | -115.942 |
Employees | 5,800 |
EBITDA | -1.3B -1.1B |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +71.81% upside |
Next Earnings | 1 May 2025 |
|---|
Market Cap | -5.9B 9.7B |
|---|---|
Previous open | 24.25 |
Previous close | 27.34 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Moderna Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Moderna Inc Forecast
Price Target
By TipRanks
71.81% upside
12 Months Forecast
Average 47.06 USD 71.81%
High 212 USD
Low 23 USD
Based on 19 Wall Street analysts offering 12 month price targets forModerna Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Moderna Inc
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
